Completed PHASE2 INTERVENTIONAL NCT00099593

Immunization Against Tumor Cells in Sezary Syndrome

Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells

Sponsor: University of Pittsburgh

Conditions Cutaneous T-cell Lymphoma Sezary Syndrome

Interventions Autologous Dendritic Cell Vaccine

Updated 5 times since 2017 Last updated: Mar 24, 2015 Started: Sep 30, 2004 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00099593, this PHASE2 trial focuses on Cutaneous T-cell Lymphoma and Sezary Syndrome and remains completed. Sponsored by University of Pittsburgh, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Pittsburgh

Data source: FDA Office of Orphan Products Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States